Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tofacitinib versus etanercept and placebo in moderate to severe chronic plaque psoriasis
NL-OMON38163Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib and etanercept in psoriasis (4 arms), sponsored by Pfizer. Primary endpoints: Physician's Global Assessment response at Week 12 and PASI75 response at Week 12. Started Mar 2012; status: active, not recruiting.
02
Drugs
tofacitinibetanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON38163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38163.